key: cord-0683967-dccue6md
authors: Meppiel, E.; Peiffer-Smadja, N.; Maury, A.; Bekri, I.; Delorme, C.; Desestret, V.; Gorza, L.; Hautecloque-Raysz, G.; Landre, S.; Lannuzel, A.; Moulin, S.; Perrin, P.; Petitgas, P.; Sellal, F.; Wang, A.; Tattevin, P.; de Broucker, T.; registry, contributors to the NeuroCOVID
title: Neurological manifestations associated with COVID-19: a nationwide registry
date: 2020-07-16
journal: nan
DOI: 10.1101/2020.07.15.20154260
sha: 2bd5496eddf8430898e6f0e7655be129b18b7ac6
doc_id: 683967
cord_uid: dccue6md

Objective. To analyze the spectrum and characteristics of neurological manifestations associated with SARS-CoV-2 infection. Methods. We conducted a nationwide, multicentric, retrospective study during the French COVID-19 epidemic in March-April 2020. All COVID-19 patients with de novo neurological manifestations were eligible. Results. We included 222 COVID-19 patients with neurological manifestations from 46 centers throughout the country. Median age was 65 years (IQR 53-72), and 136 patients (61.3%) were male. COVID-19 was severe or critical in almost half of the patients (102, 45.2%). Brain imaging was performed in 192 patients (86.5%), including 157 MRI (70.7%). Cerebrospinal fluid was analyzed in 97 patients (43.7%), with positive SARS-CoV-2 PCR in 2 out of 75 tested (2.7%). The most common neurological diseases were COVID-19 associated encephalopathy (CAE, 67/222, 30.2%), acute ischemic cerebrovascular syndrome (AICS, 57/222, 25.7%), encephalitis (21/222, 9.5%), and Guillain-Barre Syndrome (GBS, 15/222, 6.8%). Neurological manifestations appeared after first COVID-19 symptoms with a median delay of 6 days in CAE, 7 days in encephalitis, 12 days in AICS and 18 days in GBS. Around 25% of CAE and AICS were inaugural and 30% of CAE and encephalitis were diagnosed after discontinuation of sedation. Less common manifestations were also described, including meningitis and cranial neuropathy. The median follow-up of the patients was 24 days, with a particularly high short-term mortality rate in patients with CAE and AICS (19/124, 15.3%). Interpretation. Neurological manifestations associated with COVID-19 mainly included CAE, AICS, encephalitis and GBS. Clinical spectrum and outcomes were broad and heterogeneous, suggesting different underlying pathogenic processes.

, the disease linked to the SARS-CoV-2 coronavirus, is an emerging infectious disease with first cases reported in China in December 2019. Since then, the virus has continued to spread and on March 11 , 2020 the World Health Organization (WHO) characterized COVID-19 as a pandemic.

France has been heavily affected by the COVID-19 epidemic and went into lockdown on March 17, 2020 . From March 1, 2020 to April 30,2020, 89 818 new cases of COVID-19 were hospitalized in France. Up to July 2, 2020, more than 160,000 cases and 29,000 deaths had been reported in France.

Although common manifestations of the disease including respiratory tract and associated systemic manifestations have been well described 1,2 , neurological manifestations elicited few communications.

Headaches, dizziness, anosmia, encephalopathy and strokes have been reported in cohort studies 3, 4 .

However, the potential pathogenesis of SARS-CoV-2 in the central nervous system remains unclear 5 , and the range of neurological disorders associated with COVID-19 is not fully defined.

The present study aims to provide a comprehensive overview of neurological manifestations associated with SARS-CoV-2 infection and to describe the clinical course and outcomes of COVID-19 patients with neurological manifestations.

We conducted a nationwide retrospective, multicentric, observational study to collect neurological manifestations associated with COVID-19. A case report form (CRF) containing the main information regarding COVID-19 and neurological manifestations was sent at regular intervals from March 16 to April 27, 2020 to neurologists, infectious diseases specialists and intensivists through the National College of General Hospital Neurologists (CNNHG), the French Society for Infectious Diseases (SPILF), the Association of French-Speaking Liberal Neurologists (ANLLF), and the Multiple Sclerosis Society (SF-SEP). The anonymized CRF were collected by email or telefax at the Neurology department of Saint-Denis Hospital, France. In accordance with French law, the study complied with the Commission Nationale de l'Informatique et des Libertés (CNIL, reference number 2217844) and ethics committee (reference number RCB 2020-A01300-39) requirements. The IRB CER-MIT n° 2020-0602 COVID has approved the study.

We included COVID-19 adult patients with any neurological manifestations occurring 5 days before to 35 days after the first symptoms of COVID-19. COVID-19 patients managed in intensive care units with neurological manifestations after withdrawal of sedation were also included. Only de novo neurological symptoms were considered, excluding patients with exacerbations of chronic neurological diseases.

A confirmed case of COVID-19 was defined as a patient with a positive SARS-CoV-2 RT-PCR assay on a naso-pharyngeal sample or a positive SARS-CoV-2 serology (according to local laboratory standard). As RT-PCR analysis and serology were unavailable in some centers during the epidemic, some cases were considered COVID-19 if the clinical history and the chest CT-scan were considered typical according to local expert clinicians. We defined the severity of COVID-19 illness as mild, moderate, severe and critical according to NIH guidelines 6 . Demographical and clinical data, neurological workup findings and outcome were systematically collected. If necessary, in-charge clinicians were directly contacted to collect any missing or uncertain records.

Neurological manifestations were split into Central Nervous System (CNS) and Peripheral Nervous System (PNS) manifestations. Each manifestation was then classified into the following diagnostic categories:

-Stroke was considered in patients with sudden neurological deficit related to an acute vascular lesion on cerebral MRI or CT scan (ischemic and hemorrhagic stroke), in patients with transient focal deficit and normal MRI (transient ischemic attack), or in patients with cerebral venous thrombosis.

-Encephalitis was defined as altered mental status lasting ≥ 24 hours and one of the following criteria: white blood count cells (WBCs) in cerebrospinal fluid (CSF) > 5/mm 3 ; presence of compatible acute lesion on brain MRI.

-Encephalopathy was defined by delirium lasting ≥ 24 hours, and could be associated to seizure and/or focal neurological sign, in the absence of criteria for encephalitis criteria. We defined COVIDassociated encephalopathy (CAE) if encephalopathy could not be accounted for by another cause such as toxic or metabolic factor according to the reporting clinician.

-Guillain-Barré Syndrome (GBS) was defined according to standard diagnosis criteria 7 .

-Acute meningitis was defined as meningeal syndrome without encephalitic course, and CSF WBC counts > 5/mm 3 .

-Patients with neurological manifestations that could not be classified into these five categories were classified as 'others'

The study was conducted in March-April 2020. Among the 259 CRF submitted, 37 patients were excluded for the following reasons: COVID-19 not confirmed (n=20), neurological symptoms non time-related to other symptoms of COVID-19 (n=12) or neurological symptoms linked to an exacerbation of chronic neurological disease (n=5). The population study ( Figure 1) died, mostly following acute respiratory distress syndrome (ARDS, n=17, 7.7%). Stroke was considered to be the cause of death in five patients (2.3%), following brain herniation due to extensive spontaneous intracerebral hematoma (n=2), severe hemorrhagic transformation after ischemic stroke (n=2) or extensive cerebral venous thrombosis (n=1).

The spectrum of the neurological manifestations associated with SARS-CoV-2 infection is presented in Figure 1 .

One hundred eighty-nine patients (85.1%) had CNS manifestations, mostly encephalopathy (n=85, 38 .3% of all patients), strokes (n=63, 28.4%), and encephalitis (n=21, 9.5%).

The distribution of strokes was as follows: acute ischemic cerebrovascular syndromes (AICS, 57/63, 90.5% of all strokes) including 52 acute ischemic strokes and 5 transient ischemic attacks, intracranial hemorrhages (ICH, 5/63, 7.9%) and cerebral venous thromboses (CVT, 1/63, 1.6%).

Among patients with encephalopathy, 67/85 (78%) were classified as COVID-associated encephalopathy (CAE). The 18 remaining patients had other factors accounting for encephalopathy: acute kidney injury in 10, medication in 6, complications of alcohol withdrawal in 4 patients.

The other CNS manifestations were isolated seizures (n=8), transient loss of consciousness (n=5), meningitis (n=3), single acute demyelinating lesion (n=2), paraparesis (n=1) and generalized myoclonus with cerebellar ataxia (n=1).

Twenty-nine patients (13.1%) had PNS manifestations, mostly Guillain-Barré syndrome (GBS, n=15, 6.8% of all patients). Ten other patients had peripheral complications of intensive care management, either critical illness neuropathy (n=8) or hypoglossal and pneumogastric nerves palsy following orotracheal intubation, known as Tapia syndrome (n=2).

The remaining PNS manifestations were cranial neuropathy (n=3) and bilateral fibular nerve palsy (n=1). Eleven patients (5.9%) had mixed CNS and PNS manifestations, as detailed in Figure 1 .

Fifteen patients (6.8%) had mixed manifestations of undetermined mechanisms, including headache, dizziness, anosmia, auditory symptoms and subjective sensitive symptoms, in different combinations. 

In AICS, focal central neurological symptoms were present in 56/57 patients (98.2%), and altered mental status in 8/57 (14.0%).

In encephalitis and CAE, all patients had altered mental status. Twelve out of 21 encephalitis patients (57.1%) had focal central neurological symptoms, mostly cerebellar ataxia and pyramidal syndrome, and six (28.6%) had movement disorders, mostly tremor and myoclonus. Focal neurological symptoms were also present in 13/67 CAE patients (19.4%) mostly cerebellar ataxia. Seizure rate was approximately the same in encephalitis (2/21, 9.5%) and in CAE (7/67, 10.4%).

In GBS patients, 11/15 patients (73.3%) had progressive weakness in both arms and legs that could be associated with sensory symptoms. Among these 11 patients, one had oculomotor nerve palsy and another had bilateral facial nerve palsy. Three other patients (20.0%) had proprioceptive sensory loss without limb weakness, associated with facial palsy in one. One patient (6.7%) had bilateral facial palsy and areflexia.

Large vessel thrombosis was observed in 16/57 patients with AICS (28.1%), located in internal carotid artery (n=9) and/or the proximal segment of the middle cerebral artery (n=6), or in basilar artery (n=1).

Thirteen patients (22.8%) had multi territory ischemic strokes. AICS was cryptogenic in 38/57 patients (66.7%). Etiological workup highlighted 9 embolic heart disease (atrial fibrillation in 4, paradoxical embolism in 2, valvular heart disease in 2, myocarditis in 1), 7 atheromatous stenosis, 1 cerebral small vessel disease, 1 intracranial vasculopathy and 1 carotid artery dissection. 

In encephalitis, 10/21 patients (47.6%) fully recovered, 3 of whom received corticosteroids (CS). In patients with persistent neurological symptoms ( 

Fifty patients had neurological manifestations that did not fulfill criteria for AICS, encephalitis, CAE or GBS, nor were they related to intensive care complications or metabolic or toxic encephalopathy.

These neurological manifestations were very heterogeneous ( Figure 1 , Table 4 ).

Three young patients, with a median age of 20 years (IQR [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , had acute benign lymphocytic meningitis in a context of mild or moderate COVID-19 disease. CSF examination demonstrated lymphocytic pleiocytosis from 12 to 102 WBC/mm 3 , a normal protein level and negative SARS-CoV-2 PCR in the two samples that were tested.

Five patients had ICH. Three of them had deep ICH with a history of chronic arterial hypertension.

Another patient had lobar ICH with no evidence of an underlying vascular malformation or tumor after extensive work-up including brain MRI and cerebral angiography. The last patient had multiple lobar ICH in a context of severe COVID-19 disease with acute kidney injury and hemolytic anemia.

Two out of the five patients with ICH (40%) died.

One patient had CVT revealed by a large parenchymal hematoma and a fulminant intracranial hypertension, causing death within a few days.

Two patients had oculomotor nerve palsy and one had facial peripheral nerve palsy with spontaneous clinical improvement in most cases (2/3, 66.7%) and no evidence for an underlying acute inflammatory demyelinating neuropathy. One patient had bilateral fibular palsy with an asymmetrical motor predominant neuropathy of undetermined mechanism.

Eight patients had isolated de novo seizure and five had transient alteration of consciousness, with resolution of symptoms in less than 24 hours and no other encephalopathic features. Semeiology of seizure were as follows: generalized tonic-clonic seizure (n=6), focal motor seizure (n=1), focal nonmotor seizure with chewing movement (n=1). One patient experienced recurrence of generalized seizure after 24 hours and required long term antiepileptic medication, with etiological negative workup.

Two young women with no medical history revealed multiple sclerosis with an acute demyelinating MRI lesion, optic neuritis in one and cerebellar peduncle active lesion in one, with several old lesions.

One patient had paraparesis of undetermined mechanism, with no evidence for myelitis on spine MRI and no evidence for Guillain-Barré syndrome on CSF examination and electroneuromyography.

Another patient had generalized myoclonus with cerebellar ataxia. Brain MRI revealed no significant abnormalities and CSF examination was not available. He improved partially without any treatment.

Fifteen patients (6.8%) had different combinations of nonspecific symptoms such as headache or dizziness, that could be associated with anosmia or hiccups. Most patients (12/15, 80%) had mild or moderate COVID-19 disease. Neurological symptoms appeared early in the evolution of the disease as they were inaugural for 5 patients and appeared in a median delay of 3 days for the others. 16 . Cases with unremarkable MRI have also been published 17, 18 . Only two patients in our registry had a positive SARS-CoV-2 PCR in the CSF. In line with our data, only two encephalitis with positive SARS-CoV-2 PCR in CSF have been reported by the time of writing 9, 15 . In our series the short-term outcome was generally favorable without any specific treatment. All of these elements suggest rather a para-infectious mechanism than a direct neuropathogenicity of the virus, but neuropathological studies remain scarce. In a recent autopsy study of six patients who died from COVID-19, Von Weyhern and al 19 23 . In the autopsy study of Von Weyhern and al 19 , diffuse petechial brain hemorrhages were associated with encephalitic pathological features, with no conspicuous endotheliitis.

Another autopsy study 24 demonstrated the presence of acute hypoxic injury in the cerebrum and cerebellum with no thrombi, encephalitis or vasculitis, and no cytoplasmic viral staining. This study concerned 18 patients having encephalopathic features associated with fatal COVID-19 disease. In our registry, we described a group of 67 patients with CAE, defined by persistent confusional state without encephalitis criteria or obvious toxic-metabolic coexisting factor. CAE patients had more severe forms of COVID-19, as previously shown in other studies 3, 8 , with one third of them exhibiting delirium after intensive care management when sedation was withdrawn. Helms et al described the same course in 67% of patients with COVID-19 related ARDS 4 . We can therefore hypothesize that COVID-induced sepsis 25 may lead to a septic-associated encephalopathy (SAE). There are indeed many points suggestive of SAE in our CAE patients: age, previous cognitive impairment, illness severity, focal deficit and seizures, tremor, myoclonus and acute vascular lesion on brain MRI 26 . SAE can also induce posterior reversible encephalopathy syndrome 27 which has not been reported in our registry but some cases have been published in COVID-19 patients 8, 28 . The release of pro-inflammatory cytokines is one of the key pathogenic pathways suggested in SAE, and is thought to play a central role in severe COVID-19 29 . The cytokine storm is also one of the possible pathogenic pathways in mild encephalopathy with reversible splenial lesion syndrome, that is described in one patient in our registry and in one patient in the literature 30 .

In patients with encephalitis and CAE, electroencephalographic features were relatively close and mainly consisted of a nonspecific generalized background slowing, indicating diffuse cerebral dysfunction. Some published cases suggested a more specific pattern in COVID-19 patients, showing in frontal areas the presence of monomorphic biphasic delta slow waves with a periodic organization 31, 32 . Our study found only 15% of anterior slowing and 9% of periodic pattern in patients with encephalitis and CAE.

AICS was the second most common manifestation in our series, accounting for 26% of patients.

Although 75% of AICS patients had vascular comorbidities, our study highlights some features for which there is growing evidence in other published series: high prevalence of large vessels stroke 33,34 , multi-territory involvement 34 , undetermined etiology 35 , and high mortality rate 35 . COVID-related coagulopathy 23 probably plays a decisive role in these thrombotic cryptogenic ischemic strokes. AICS [36] [37] [38] [39] [40] [41] and an Italian study has demonstrated that the incidence of GBS increased in their region during the COVID-19 epidemics compared with the three previous years 42 . No Miller Fisher syndrome case has been reported in our registry, and published cases are few and far between' 43, 44 .

Patients with mixed manifestations of undetermined mechanisms such as headache, dizziness, subjective sensitive signs and anosmia have been reported to our registry in about 7% of patients.

Headache and dizziness are frequently reported in cohorts of COVID-19 patients, ranging from 8 to 14% and 6 to 17% respectively 1, 3, 8 . Anosmia was present in 3% of our patients and in about 5% in other series of hospitalized COVID-19 patients 3,8 whereas its prevalence reached 86% in a dedicated European multicentric study 45 . In our cohort that mainly involved hospitalized patients, these symptoms may have been underreported.

The other neurological manifestations reported in our registry are much rarer in occurrence and would require larger studies to be appropriately described. We report three cases of acute benign lymphocytic meningitis, which has not been reported in association with COVID-19 to date. We also report two patients with Tapia syndrome, a rare complication of orotracheal intubation, with one similar case recently published 46 .

Our study has some limitations. First, this is a retrospective registry with inherent reporting biases, which should lead us to interpret with caution the different proportions of neurological manifestations.

Headache, dizziness and anosmia were not particularly frequent in our registry, probably underreported and/or associated with milder forms of COVID-19 disease. Secondly, the data are entirely descriptive and based on the report at a definite time period during the French outbreak. We used a deliberately simplified CRF given the exceptional working load of medical teams, whose first mission during the outbreak was the management of patients. There was therefore no exhaustive collection of medical history other than neurological comorbidities and vascular comorbidities for AICS, nor of biological parameters. The main objective was to provide a wide overview of neurological manifestations associated with SARS-CoV-2 infection. The analysis of the mechanisms and potential risk factors for nervous system involvement in COVID-19 is therefore limited. Further studies are necessary to clarify these points.

Our study highlights the broad spectrum of neurological manifestations associated with SARS-CoV-2 infection, probably related to different pathogenic pathways. Although encephalopathies were the most frequently reported manifestation, possibly linked to sepsis and cytokine storm, encephalitis was described in 10% of cases. However, we found few arguments to support the hypothesis of direct SARS-CoV-2 neuropathogenicity: a large majority of SARS-CoV-2 PCR in cerebrospinal fluid (73/75, 97.3%) were negative, and the short-term outcome of patients with encephalitis was generally favorable. Ischemic strokes were also frequently reported, as well as GBS, which occurred later in the course of the disease (18 days as compared to 7 days for encephalitis or 12 days for strokes). Other 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of Covid-19 in

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurologic Features in Severe SARS-CoV-2 Infection

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review

Management of COVID-19 | Coronavirus Disease COVID-19

Assessment of current diagnostic criteria for Guillain-Barr syndrome

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Acute disseminated encephalomyelitis after SARS-CoV-2 infection

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia

Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid

Brain MRI Findings in Patients in the Intensive Care Unit with COVID-19 Infection

COVID-19-White matter and globus pallidum lesions: Demyelination or small-vessel vasculitis?

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Lessons of the month 1: A case of rhombencephalitis as a rare complication of acute COVID-19 infection

Two patients with acute meningo-encephalitis concomitant to SARS-CoV-2 infection

Steroid-Responsive Encephalitis in Coronavirus Disease

Early evidence of pronounced brain involvement in fatal COVID-19 outcomes

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Endothelial cell infection and endotheliitis in COVID-19

COVID-19 Neurologic Complication with CNS Vasculitis-Like Pattern

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Neuropathological Features of Covid-19

SARS-CoV-2 and viral sepsis: observations and hypotheses

Septic-Associated Encephalopathy: a Comprehensive Review

Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature

Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection

Cytokine release syndrome in severe COVID-19

COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion

COVID-19 associated encephalopathy: Is there a specific EEG pattern?

Report of EEG Finding on Critically Ill Patients with COVID 19

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Characteristics of ischaemic stroke associated with COVID-19

SARS2-CoV-2 and Stroke in a New York Healthcare System

Guillain-Barré Syndrome Associated with SARS-CoV-2

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Guillain-Barré syndrome following COVID-19: new infection, old complication?

Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19

Guillain-Barré syndrome related to COVID-19 infection

Guillain-Barré syndrome related to SARS-CoV-2 infection

Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?

COVID-19 presenting with ophthalmoparesis from cranial nerve palsy

Miller Fisher Syndrome and polyneuritis cranialis in COVID-19

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Tapia syndrome at the time of the COVID-19 pandemic: Lower cranial neuropathy following prolonged intubation

Pitié-Salpêtrière Hospital

Secretary of the French Society of Multiple Sclerosis (SF-SEP)

Centre Hospitalier de Calais, 62100 Calais, France DEROLLEZ Céline

Department of Internal Medicine

Centre Hospitalier Mulhouse, 68100 Mulhouse, France FRAISSE Thibault, Department of Geriatric Medicine, Hôpital Alès-Cévennes, 30103 Alès, France GUGENHEIM Michel, president of the Association of French-Speaking Liberal Neurologists

We acknowledge the support of the National College of General Hospital Neurologists (CNNHG), the French Society for Infectious Diseases (SPILF), the Association of French-Speaking Liberal